Drug Trial Radar · NCT02070978
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
Last checked: Nov 20, 2026Latest source record: Mar 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
253
Actual
Start
Jul 29, 2014
Primary completion
Apr 5, 2016
Study completion Feb 9, 2018
Sponsor
- Lead sponsor
- EMD SeronoIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in participants with systemic lupus erythematosus (SLE). Participants who completed the 24-week core study ADDRESS II core study (NCT01972568) and thus not met any of the discontinuation criteria were invited to enter this long-term extension (LTE) study NCT02070978.
Conditions
- Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mgDrug
Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
Atacicept 150 mgDrug
Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
Atacicept 150 mgDrug
Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least One Serious Adverse Event (SAE) During the Treatment PeriodTime frame: Baseline (LTE Day 1) up to maximum treatment duration of 143.7 weeks
- Number of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE)Time frame: Baseline (Day 1 of Core study) up to maximum duration of 167.7 weeks
Locations
84 sites in 17 countries. Site status is shown where the registry gives one.
Pinnacle Research Group LLC
Anniston, Alabama
University of Alabama at Birmingham - (UAB)
Birmingham, Alabama
Wallace Rheumatic Study Center
Beverly Hills, California
Southern California Permenent Medical Group
Fontana, California
East Bay Rheumatology Medical Group, Inc.
San Leandro, California
Clinical Research of West Florida - Corporate
Clearwater, Florida
Clinical Research of West Florida, Inc.
Tampa, Florida
McIlwain Medical Group, PA
Tampa, Florida
AA MRC LLC Ahmed Arif Medical Research Center
Grand Blanc, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
Clayton Medical Associates, P.C.
St Louis, Missouri
Rutgers New Jersey Medical School
Newark, New Jersey
The Feinstein Institute for Medical Research
Manhasset, New York
Hospital for Special Surgery
New York, New York
DJL Clinical Research, PLLC
Charlotte, North Carolina
MetroHealth System
Cleveland, Ohio
Arthritis & Rheumatology Center of Oklahoma
Oklahoma City, Oklahoma
OMRF
Oklahoma City, Oklahoma
Clinical Research Center of Reading LLC
Wyomissing, Pennsylvania
Medical University of South Carolina (MUSC)
Charleston, South Carolina
Austin Regional Clinic, P.A.
Austin, Texas
Little River Arthritis & Osteoporosis Clinic
Waco, Texas
Organizacion Medica de Investigacion (OMI)
Ciudad Autonoma Buenos Aires, Argentina
APRILLUS
Ciudad Autonoma Buenos Aires, Argentina
Atencion Integral en Reumatologia (AIR)
Ciudad Autonoma Buenos Aires, Argentina
Hospital Privado Centro Medico de Cordoba
Córdoba, Argentina
Cordis S.A.
Salta, Argentina
Centro Polivalente de Asistencia e Inv. Clinica CER
San Juan, Argentina
Instituto CAICI
Rosario, Santa Fe Province, Argentina
Centro Medico Privado de Reumatologia
San Miguel de Tucumán, Tucumán Province, Argentina
Centro Integral de Reumatologia
San Miguel de Tucumán, Tucumán Province, Argentina
Investigaciones Clinicas Tucuman
San Miguel de Tucumán, Tucumán Province, Argentina
Centro de Pesquisas em Diabetes Ltda.
Porto Alegre, Rio Grande do Sul, Brazil
MHAT "Eurohospital" - Plovdiv, OOD
Plovdiv, Bulgaria
Medical Center "Teodora", EOOD
Rousse, Bulgaria
MHAT - Ruse, AD
Rousse, Bulgaria
UMHAT "Sv. Ivan Rilski", EAD
Sofia, Bulgaria
DCC "Sveta Anna", EOOD
Sofia, Bulgaria
Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
Stara Zagora, Bulgaria
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.